CK2 activity is crucial for proper glucagon expression

Emmanuel Ampofo,Mandy Pack,Selina Wrublewsky,Anne S. Boewe,Aliya F. Spigelman,Hanna Koch,Patrick E. MacDonald,Matthias W. Laschke,Mathias Montenarh,Claudia Götz
DOI: https://doi.org/10.1007/s00125-024-06128-1
IF: 8.2
2024-03-20
Diabetologia
Abstract:Abstract Aims/hypothesis Protein kinase CK2 acts as a negative regulator of insulin expression in pancreatic beta cells. This action is mainly mediated by phosphorylation of the transcription factor pancreatic and duodenal homeobox protein 1 (PDX1). In pancreatic alpha cells, PDX1 acts in a reciprocal fashion on glucagon (GCG) expression. Therefore, we hypothesised that CK2 might positively regulate GCG expression in pancreatic alpha cells. Methods We suppressed CK2 kinase activity in αTC1 cells by two pharmacological inhibitors and by the CRISPR/Cas9 technique. Subsequently, we analysed GCG expression and secretion by real-time quantitative RT-PCR, western blot, luciferase assay, ELISA and DNA pull-down assays. We additionally studied paracrine effects on GCG secretion in pseudoislets, isolated murine islets and human islets. In vivo, we examined the effect of CK2 inhibition on blood glucose levels by systemic and alpha cell-specific CK2 inhibition. Results We found that CK2 downregulation reduces GCG secretion in the murine alpha cell line αTC1 (e.g. from 1094±124 ng/l to 459±110 ng/l) by the use of the CK2-inhibitor SGC-CK2-1. This was due to a marked decrease in Gcg gene expression through alteration of the binding of paired box protein 6 (PAX6) and transcription factor MafB to the Gcg promoter. The analysis of the underlying mechanisms revealed that both transcription factors are displaced by PDX1. Ex vivo experiments in isolated murine islets and pseudoislets further demonstrated that CK2-mediated reduction in GCG secretion was only slightly affected by the higher insulin secretion after CK2 inhibition. The kidney capsule transplantation model showed the significance of CK2 for GCG expression and secretion in vivo. Finally, CK2 downregulation also reduced the GCG secretion in islets isolated from humans. Conclusions/interpretation These novel findings not only indicate an important function of protein kinase CK2 for proper GCG expression but also demonstrate that CK2 may be a promising target for the development of novel glucose-lowering drugs. Graphical Abstract
endocrinology & metabolism
What problem does this paper attempt to address?
This paper aims to explore the regulatory role of protein kinase CK2 on glucagon (GCG) expression in pancreatic islet α - cells. Specifically, based on previous research findings that CK2 inhibits insulin expression in pancreatic islet β - cells by phosphorylating the transcription factor PDX1, the researchers speculated that CK2 might positively regulate glucagon expression in pancreatic islet α - cells. To verify this hypothesis, the researchers inhibited or knocked out CK2 activity in αTC1 cells through pharmacological inhibitors and CRISPR/Cas9 technology, and analyzed the effects of these operations on glucagon expression and secretion. ### Main research questions 1. **Does CK2 positively regulate glucagon expression in pancreatic islet α - cells?** - The researchers observed changes in glucagon expression and secretion by inhibiting or knocking out CK2 activity. 2. **What is the regulatory mechanism of CK2 on glucagon expression?** - The researchers analyzed the binding of transcription factors PAX6 and MafB to the glucagon promoter region after CK2 inhibition or knockout. ### Research methods - **Pharmacological inhibition**: αTC1 cells were treated with CK2 inhibitors CX - 4945 and SGC - CK2 - 1. - **Gene editing**: The CK2α subunit in αTC1 cells was knocked out using CRISPR/Cas9 technology. - **Molecular biology techniques**: Including real - time quantitative RT - PCR, Western Blot, luciferase reporter gene assay, DNA pull - down assay, etc., to detect glucagon expression, secretion and transcription factor binding. - **In vivo experiments**: αTC1 cells were transplanted under the mouse renal capsule to observe the effects of CK2 inhibition on glucagon expression and blood glucose levels. ### Main findings - **CK2 inhibition or knockout significantly reduced glucagon secretion in αTC1 cells**, from 1094 ± 124 ng/l to 459 ± 110 ng/l. - **CK2 inhibition or knockout reduced the level of Gcg mRNA**, indicating that CK2 mainly regulates glucagon expression at the transcriptional level. - **Binding of transcription factors MafB and PAX6**: CK2 inhibition or knockout led to a decrease in the nuclear localization of MafB, while the nuclear localization of PAX6 was not affected. - **In vivo experiments**: CK2 inhibition or knockout also reduced glucagon secretion in the mouse model, further supporting the important role of CK2 in glucagon expression. ### Conclusion The research results not only confirm the function of CK2 in positively regulating glucagon expression in pancreatic islet α - cells, but also reveal the mechanism by which CK2 regulates glucagon expression by affecting the nuclear localization of the transcription factor MafB. These findings provide a new target for the development of new hypoglycemic drugs.